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Objectives: To estimate the dosage needed for continuous infusion and to investigate whether continuous infusion of the
ultrasound contrast-enhancing agent Levovist (SH U 508A) can improve duplex scanning of crural arteries in patients
with peripheral arterial obstructive disease (PAOD) eligible for distal bypass graft surgery.
Design, patients, and methods: The study design consisted of two parts. Part 1 investigated the color and spectral Doppler
scan enhancement of three different Levovist dosages (200, 300, and 400 mg/mL) in one arterial segment of a patent
lumen of a crural artery in seven patients with PAOD. Part 2 investigated the value of the optimum Levovist dosage in
the assessment of 10 crural arteries in 10 consecutive patients with PAOD. Angiography was the reference standard.
Results: Part 1: Levovist significantly enhanced color and spectral Doppler scan as compared with baseline ultrasound
scan, but no differences were found between the Levovist dosages. Thus, the lowest Levovist dosage sufficed for
application in part 2, because of its infusion volume and prolonged enhancement time. Part 2: The agreement between
contrast-enhanced duplex scanning and angiography was moderate (  0.50; 95% confidence interval [CI], 0.03-0.97).
Five (50%) of 10 crural arteries that could not adequately be visualized with routine duplex scanning could be visualized
with contrast-enhanced duplex scanning.
Conclusion: Contrast-enhanced duplex scanning by means of continuous infusion of Levovist in patients with PAOD
improves the ultrasound scan investigation of crural arteries in case routine duplex scanning is inconclusive and might
reduce the need for angiography. (J Vasc Surg 2004;39:517-22.)
Duplex scanning is increasingly used for clinical deci-
sion making in patients with severe lower-leg ischemia. It
has been shown that in a vascular unit with expertise in
duplex scanning of the lower-leg arteries, management of
patients with severe ischemia can be based on duplex scan-
ning in most patients.1 Nevertheless, it is sometimes diffi-
cult or even impossible to assess the patency and blood flow
of the crural arteries (peroneal artery [PA], anterior tibial
artery [AT] and posterior tibial artery [PT]). This difficulty
is due to several factors, such as edema of the calf, heavy
calcification of the arterial wall, and low-velocity blood flow
in the crural arteries. In these instances, echo enhancement
by ultrasound scan contrast agents could be a useful aid to
increase the sensitivity and accuracy of duplex scanning of
crural arteries.
Levovist (SH U 508A; Schering, Berlin, Germany) is a
galactose-based echo-enhancing contrast agent.2,3 It is an
intravenously administered, transpulmonary stable agent
that contains air microbubbles. These air microbubbles
increase echogenicity of the arterial blood flow. The con-
trast agent has been shown to improve the diagnostic
confidence of duplex scanning in a wide range of applica-
tion areas: the heart; peripheral, carotid, and transcranial
arteries and veins; and tumor vessels.4-11 These and several
others studies injecting this contrast medium as a bolus
have described a typical wash-in and washout enhancement
curve: a rapid increase followed by a short strong enhance-
ment (in the order of 2-5 minutes), with subsequent decay
over a few minutes.12-16 This enhancement pattern implies
that the duration of diagnostically useful Doppler scan
signal enhancement is relatively short, whereas proper ul-
trasound scanning of the crural vessels requires at least
several minutes of optimum visualization. This limitation
can be overcome by administration of Levovist through
continuous infusion, which prolongs Doppler scan signal
enhancement.17-24
The aim of this study was twofold. To find a suitable
Levovist dosage for continuous infusion and to assess the
value of continuous infusion of Levovist in the appreciation
of blood flow characteristics to assess the patency of crural
arteries by means of contrast-enhanced duplex scanning in
patients with peripheral arterial obstructive disease
(PAOD).
PATIENTS AND METHODS
The study design consisted of two parts. In part 1 we
investigated which continuous infusion dosage of Levovist
is needed for optimum assessment of crural arteries in
patients with PAOD. This study was done in a patent crural
artery. In part 2 we investigated the value of this optimum
dosage of Levovist through continuous infusion in the
From the Unit of Vascular Surgery, Academic Medical Center, Amsterdam.
Competition of interest: none.
Additional material for this article may be found online at www.mosby.
com/jvs.
Reprint requests: D. Th. Ubbink, MD, PhD, Unit of Vascular Surgery,
G4-109.2, Academic Medical Center, Meibergdreef 9, 1105 AZ Amster-
dam, The Netherlands. (e-mail: D.Ubbink@amc.uva.nl).
Published online Jan 30, 2004.
0741-5214/$30.00
Copyright © 2004 by The Society for Vascular Surgery.
doi:10.1016/j.jvs.2003.10.037
517
appreciation of crural arteries in patients with PAOD. Be-
tween November 2001 and May 2002, patients suffering
from PAOD were referred to our vascular laboratory for
routine crural duplex scanning and were considered as
potential candidates for inclusion in this study. All the
patients had an ankle-brachial index (ABI) 90 at rest or
after treadmill exercise, indicating the presence of arterial
insufficiency.
Duplex scans were performed with 4.5 to 7.5 MHz
B-mode linear or curved-linear probes incorporating a 3.7-
MHz Doppler scan probe (Hewlett Packard Sonos 2000;
Hewlett Packard, Andover, Mass). The PA was examined
with the patient in the lateral position, the AT and PT
arteries were examined with the patient in the supine posi-
tion. Duplex scans of the crural arteries were performed
over the entire length of the arteries. The patency of the
crural arteries was graded according to a semiquantitative
scoring system25-27 as follows: 2, no or minor vessel wall
irregularities as seen on B-mode imaging and fully patent
lumen determined by the presence of a color signal; 1,
severe vessel wall irregularities (B-mode), diffuse luminal
narrowing (color Doppler scan or peak systolic velocity
[PSV] changes detected by pulsed Doppler scan), or an
isolated stenosis of50% diameter reduction (defined by a
PSV ratio 2.5 m/s); 0, occlusion indicated by present
vessel wall (B-mode) but absence of color and pulsed
Doppler scan signal. A segment that demonstrated both
stenosis and occlusion was considered to be occluded. If a
crural artery or crural artery segment could not be evaluated
adequately (equivocal), eg, because of poor visibility, du-
plex scanning was considered nondiagnostic.
In both study parts, contrast-enhanced duplex scan-
ning was performed within 3 weeks after routine duplex
scanning. The medical ethical committee of our hospital
approved the study, and written informed consent was
obtained from all patients.
Levovist. Levovist is supplied as granules of aggre-
gated galactose microparticles (vials containing 2.5 or 4 g)
with a very low concentration of palmitic acid (99.9 %
galactose, 0.1 % palmitic acid). With the addition of water
for injection, microbubbles (smaller than 10 m) filled
with air and stabilized by palmitic acid are formed. The
Levovist microbubbles are small enough to survive the
pulmonary transit. Vials containing 4 g of Levovist granules
were used in this study. Three different Levovist dosages
can be prepared for the administration, depending on the
amount of water for injection added to the 4 g of Levovist
granules28 (Table I, online only). For the continuous infu-
sion of Levovist, a specifically configured pump injector was
used (Medrad Pulsar Ultrasound Injection System; Medrad
Europe BV, Maastricht, The Netherlands). The infusion
rate was 1.5 mL/min throughout the whole investigation.
A Levovist bolus of 2 mL was injected by the pump injector
immediately followed by administration of the remaining
volume as continuous infusion. Reported adverse effects of
Levovist are transient pain and sensation of warmth or cold
in the area of the injection site, sensation of taste, dyspnea,
nausea, and vomitus. Levovist is hyperosmotic and should
be avoided in patients with severe cardiac failure (New York
Heart Association [NYHA] stage IV). Patients were in-
structed to notify the investigators in case of any undesir-
able effects.
Part 1: Dose finding. Inclusion criteria were patients
with PAOD of the crural arteries potentially eligible for
therapeutic intervention. They should have at least one
patent crural artery (as seen on B-mode imaging and spec-
tral analysis during routine duplex scan examination), in
which the enhancement effect could be studied. For this
purpose the best visible segment (proximal, middle, or
distal) of one patent crural artery was chosen. Exclusion
criteria were based on the contraindications for the admin-
istration of Levovist. These criteria were the presence of
severe heart failure, pregnancy, galactosemia, and acute
lower-limb ischemia. Patients with acute limb ischaemia
were excluded, because they are supposed to undergo
emergency treatment. Lesions in the aortoiliac and/or
femoropopliteal tract were not a contraindication for inclu-
sion. Thus, the color and spectral Doppler scan enhance-
ment of three different Levovist dosages (Table I, online
only) were investigated in seven consecutive patients.
Investigation protocol. Routine duplex scanning
(without contrast enhancement) was performed with the
use of standard settings to localize and mark the arterial
segment of interest. Subsequently, the color and spectral
Doppler scan power and gain were reduced to the lowest
level that still allowed assessment of the segment of interest
in anticipation of the enhanced contrast. This setting was
kept for both the baseline duplex scan investigation and
duplex scan investigations with Levovist to enable compar-
ison of the effect of the three Levovist dosages and because
the maximum Doppler scan transmit power setting could
potentially destroy the Levovist microspheres. The wall
filter setting was kept at 50% in all patients.
The Levovist suspensions were prepared as described
by the manufacturer’s instructions. We did not use the
mini-spike (a cannula with a sharp end used to pierce the
rubber stopper of the vial) included in the package because
it did not allow transfer of the total Levovist suspension
into the pump injector. Instead, we used a flexible cannula
of sufficient gauge size. Levovist was given intravenously by
way of a 20-gauge cannula (Venflon 20G 1.26IN 1.0 32
mm; Becton Dickinson infusion therapy AB, Sweden) in
the antecubital fossa. Each patient received three different
Levovist dosages (Table I, online only) in random order by
means of continuous infusion. Simultaneously, duplex
scanning of the arterial segment of interest was performed
by an experienced vascular technologist who was blinded to
the Levovist dosage. Contrast-enhanced duplex scanning
was terminated when the Levovist volume for each dosage
in the pump injector was finished (Table I, online only). An
interval of at least 10 minutes was taken between each
administration to ensure total disappearance of contrast
enhancement from the previous administration. During
this interval the Levovist suspension for the next adminis-
tration was prepared. Preparation of the Levovist suspen-
sion and control of the injection pump were done by the
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investigator (S.C.). Duplex scan examinations were re-
corded on S-VHS videotapes for off-line analysis.
Two independent observers (D.U. and D.H.), who
were blinded to the Levovist dosage given, reviewed the
videotapes. Color and spectral Doppler scan enhancements
were graded according to the following categorical scoring
system used in similar studies to appreciate clinically rele-
vant enhancement29: 0  absence of Doppler scan color/
spectral Doppler scan, 1  poor visualization of Doppler
scan color/spectral Doppler scan, 2 average visualization
of Doppler scan color/spectral Doppler scan, and 3 
optimal visualization of Doppler scan color/spectral Dopp-
ler scan. Color Doppler and spectral Doppler scan enhance-
ments were defined as the improved visualization of the
color and spectral Doppler scan.
The degree of excessive enhancement of the color
Doppler scan outside the vessel wall (blooming) was graded
as follows: 0  no excessive enhancement, 1  excessive
enhancement but not obscuring the vessel wall, and 2 
excessive enhancement that compromised the image qual-
ity.
Angiography was performed within 6 weeks after con-
trast-enhanced duplex scanning. The differences in visual-
ization scores as found between baseline and the three
Levovist dosages, as well as the differences among the three
Levovist dosages, were compared statistically using the chi
square test for categorical data. Calculations were per-
formed with the statistical software SPSS 10.0.7 for Win-
dows (SPSS Inc, Chicago, Ill).
Part 2: Contrast-enhanced duplex scanning with
the optimum dosage of Levovist. Patients with PAOD
and who were potentially eligible for therapeutic interven-
tion were included in case the crural artery that appeared
the best runoff artery for a bypass graft procedure could not
be adequately evaluated, eg, invisibility of blood flow be-
cause of vessel wall calcification, severe vessel wall irregu-
larities, or a very low blood flow velocity (10 cm/s),
showed one or more stenoses of50% diameter reduction
(PSV ratio 2.5 m/s); or had one or more occlusions.
Lesions in the aortoiliac and/or femoropopliteal tract
were not a contraindication for inclusion. Exclusion criteria
were identical to those in part 1. The investigation protocol
was the same as in study part 1, except that here only the
optimum Levovist dosage was administered and standard
ultrasound scan settings were applied but with a reduced
Doppler scan transmit power.
Agreement between angiography, routine duplex scan-
ning, and contrast-enhanced duplex scanning as to the
patency, stenosis of 50%, or occlusion of the crural arterial
segments was compared using kappa () analysis. Kappa is a
measure of agreement beyond chance. Strength of the
agreement can be interpreted as poor (  0.20), fair (
0.21-0.40), moderate ( 0.41-0.60), good ( 0.61-0.80),
and excellent ( 0.81-1.00).
RESULTS
Part 1: Dose finding. We prospectively studied seven
patent lumina of the best visible crural artery in seven
consecutive patients (six men, one woman) with PAOD.
All patients were candidates for therapeutic intervention.
No patients were excluded on the basis of the initial exclu-
sion criteria. The patients’ median age was 77 years (range,
60-88 years). The median ABI of these patients at rest was
0.53 (range, 0-0.92). Two patients had rest pain and five
had intermittent claudication. The crural arterial segments
studied were located in the PT in 2, the PA in 1, and the AT
in 4 cases. On the angiograms, all seven segments investi-
gated were found open, without significant stenosis.
The ultrasound scan color gain settings varied between
63% and 90%, the Doppler scan gain between 50% and 95%.
The color Doppler scan range varied individually with the
severity of the stenoses. The reduction of color and Dopp-
ler scan transmit power settings ranged from 8 to 29 dB,
and from 10 to 33 dB, respectively. All seven patients also
showed an occlusion of the superficial femoral artery on the
target side but no significant aortoiliac lesions. Baseline
duplex scanning and contrast-enhanced duplex scanning
using the three different dosages of Levovist were com-
pleted within 70 minutes. No adverse effects were observed
during Levovist administration. Both observers found a
significant Doppler scan color enhancement after Levovist
administration as compared with baseline duplex scanning
(P .35 and P .003, respectively; Table II, online only).
The two observers found no blooming or an otherwise
compromised image quality during continuous Levovist
infusion. A significant spectral Doppler scan signal en-
hancement was found for the first observer (P  .03) but
not for the second observer (P  .36; Table III, online
only). No enhancement differences were found between
the three Levovist dosages. Hence, the lowest Levovist
dosage sufficed for application in the second study part
because of the higher infusion volume available, and, thus,
a prolonged enhancement time (Table I, online only).
Part 2: Contrast-enhanced duplex scanning with a
Levovist dosage of 200 mg/mL. Subsequently, we pro-
spectively studied 10 crural arteries in 10 consecutive pa-
tients (six men, four women) with PAOD by means of
contrast-enhanced duplex scanning with continuous infu-
sion of Levovist dosage of 200 mg/mL. All patients were
potentially eligible for therapeutic intervention. The pa-
tients’ median age was 75 years (range, 49-94 years). The
median ABI of these patients at rest was 0.54 (range,
0.26-0.94). Four patients had intermittent claudication, 5
patients had rest pain, and 1 had tissue loss. The crural
arteries studied were the PT in 1, the TP in 1, the AT in 6,
and the PA in 4 cases. All 10 patients showed an occluded
superficial femoral artery on the target side but no signifi-
cant aortoiliac lesions. Results of crural artery assessment
and the amount of Levovist administered are listed in Table
IV (online only). No adverse effects were observed during
Levovist administration. No patients were excluded on the
basis of the initial exclusion criteria. Blooming or compro-
mised image quality during continuous Levovist infusion
dosage of 200 mg/mL was not observed. The agreement
between contrast-enhanced duplex scanning and angiogra-
phy in the assessment of crural arteries in patients with
JOURNAL OF VASCULAR SURGERY
Volume 39, Number 3 Coffi et al 519
PAOD was moderate (  0.50; 95% confidence interval
[CI], 0.03-0.97). The agreement between routine duplex
scanning and angiography was poor (  0.13; 95% CI,
0.23 to 0.48]). Thus, the agreement between angiogra-
phy and crural duplex scanning combined with continuous
Levovist infusion was improved from poor (  0.13) to
moderate (  0.50). Results of kappa analysis are listed in
Table V (online only). Five (50%) of 10 crural arteries that
could not adequately be visualized with routine duplex
scanning could be visualized with contrast-enhanced du-
plex scanning. In one case routine duplex scanning and
angiography could not visualize a crural artery, whereas
contrast-enhanced duplex scanning did. In retrospect, this
could have been a collateral vessel.
DISCUSSION
To date there are few reports of contrast-enhanced
duplex scanning by continuous infusion in the assessment
of PAOD.17,24 Studies using a single-dose technique de-
scribed a considerable ultrasound scan enhancement after
the injection of the contrast agent as a bolus, which permit-
ted the clinical questions to be answered adequately. Un-
fortunately, this ultrasound scan enhancement is not con-
stant and of short duration, whereas proper ultrasound scan
examination of the crural vessels requires several minutes of
visualization. This study showed that continuous infusion
of Levovist has the potential to overcome this limitation
and enhances the assessment of crural vessels that could
serve as receptor artery for peripheral bypass graft surgery.
All three Levovist dosages were found to be effective
for continuous infusion in contrast-enhanced duplex scan-
ning of the crural arteries: They all yielded clinically effec-
tive enhancement of Doppler scan signals. A Levovist con-
centration of 200 mg/mL permitted 13 minutes of
Doppler scan signal enhancement, whereas higher dosages
were accompanied with a shorter infusion time, without
better visualization. A lower Levovist concentration is as-
sociated with less viscosity and is insufficiently stable and
not suitable for continuous infusion.28 Although cost anal-
ysis was not the purpose of this study, it is an aspect to take
in consideration. In 8 of the 10 crural arteries examined,
one Levovist vial (4 g) was sufficient. Higher dosages (300
and 400 mg/mL) will require a higher number of Levovist
vials per session, which leads to higher costs.
The duration of the Doppler scan signal enhancement
depends on the length of the Levovist infusion.17 Theoret-
ically, one might extend the infusion length to a much
longer period of time by applying more of the same Levo-
vist dosage up to a maximum of six vials. However, in
clinical practice only selected crural arteries or arterial seg-
ments, in which routine duplex scanning is not conclusive,
need to be studied by means of continuous infusion of
Levovist. Langholz et al11 examined the iliac, upper- and
lower-leg artery segments, injecting Levovist as a bolus,
and demonstrated that a Levovist dosage of 200 mg/mL
can also provide diagnostically effective enhancement. We
chose an infusion rate of 1.5 mL/min to achieve a stronger
Doppler scan signal enhancement. This choice was also
based on the recommended Levovist infusion dosage ad-
ministration (approximately 1-2 mL/min).28 Albrecht et
al17 compared different Levovist infusion rates in healthy
volunteers; the lowest Levovist infusion rates, ranging from
0.86 to 1.28 mL/min, were shown to induce optimal
prolongation of Doppler scan signal enhancement.
In this study we used a categorical scoring system to
classify the visualization enhancement by Levovist. This
system was also used in previous studies to appreciate the
enhancement by various contrast agents.17,29-31 It allows
for the detection of clinically relevant amount of enhance-
ment, because correct judgment of arterial patency and
stenosis depends on the visibility of the blood flow.
A semiquantitative patency scoring system was used
here to assess the patency of the crural arteries. In previous
studies, a moderate-to-good reproducibility and agreement
with angiography was found for this scoring system.26,27
One would preferably apply more objective criteria, eg, the
PSV ratio. However, the diagnostic usefulness of the PSV
ratio for crural arteries has not yet been established. Nev-
ertheless, a PSV ratio of 2.5 m/s as indicator for a
diameter reduction 50% was part of this scoring system.
Moderate (  0.50) agreement was found between
contrast-enhanced duplex scanning using continuous infu-
sion of a Levovist dosage 200 mg/mL and angiography.
Table V. Interobserver agreement between angiography,
routine DS, and contrast-enhanced DS for the assessment
of crural arteries expressed as -values
  0.13 (95% CI,
0.23 to 0.48)
Angiography
TotalPatent Stenosis Occlusion
Routine
duplex
scanning
Patent 0 0 0 0
Stenosis 1 2 1 4
Occlusion 1 0 1 2
Equivocal 0 0 4 4
Total 2 2 6 10
  0.50 (95% CI,
0.03 to 0.97)
Angiography
TotalPatent Stenosis Occlusion
Enhanced
duplex
Patent 1 0 1 2
Stenosis 0 2 1 3
Occlusion 1 0 4 5
Total 2 2 6 10
  0.28 (95% CI,
0.04 to 0.76)
Enhanced duplex scanning
TotalPatent Stenosis Occlusion
Routine
duplex
scanning
Patent 0 0 0 0
Stenosis 1 3 0 4
Occlusion 0 0 2 2
Equivocal 1 0 3 4
Total 2 3 5 10
DS, Duplex scanning; Patent, no or minor vessel wall irregularities as seen on
B-mode imaging and fully patent lumen; Stenosis, diameter reduction 
50%; Occlusion, presence of vessel wall (B-mode) but absence of color and
pulsed Doppler scan signal; Equivocal, poor visualization of the vessel
(B-mode) and the blood flow (color Doppler scan).
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Eiberg et al24 report a similar study. They also found a
moderate agreement (  0.45). They applied a Levovist
infusion rate and dosage of 1 mL/min and 300 mg/mL,
respectively. Our study differs from that of Eiberg et al24
because we included both inconclusive crural duplex scan
examinations and multiple severe crural lesions. Moreover,
we also included a Levovist dose-finding study. The present
study shows a better agreement, probably because of the
higher Levovist infusion rate of 1.5 mL/min.
The agreements between routine crural duplex scan-
ning versus angiography were poor. This finding is due to
the fact that in this study we did not include the entire
spectrum of patients with PAOD of the crural arteries,
which varies from minimal to severe arterial occlusive dis-
ease. Preliminary studies with (continuous infusion of)
Levovist for PAOD have reported to improve not only the
image quality but also the clinical diagnostic confidence.
Our results add to these findings the efficacy and tolerabil-
ity of continuous infusion of Levovist in the assessment of
crural arteries by means of duplex scanning in patients with
PAOD who require therapeutic intervention. Despite the
relatively small number of crural arteries included in this
study, as illustrated by the wide confidence intervals, we
were able to demonstrate the efficacy of continuous infu-
sion of Levovist in the assessment of the patency of crural
arteries by means of duplex scanning.
We conclude from this study that contrast-enhanced
duplex scanning by means of continuous infusion of Levo-
vist improves the assessment of the patency of crural arteries
in patients with PAOD who require peripheral bypass graft
surgery in case routine duplex scanning is inconclusive. It
could further reduce the need for diagnostic angiography.
In other vascular applications in which prolonged visualiza-
tion of vessels or vessel segments is needed, continuous
infusion of Levovist can be of additive value.
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